SCI Pharmtech Inc
TWSE:4119
Operating Margin
SCI Pharmtech Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| TW |
S
|
SCI Pharmtech Inc
TWSE:4119
|
9.9B TWD |
11%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
793.6B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
393.8B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.3T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
246.5B CHF |
32%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
235.8B USD |
36%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
180B GBP |
23%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
200.9B CHF |
32%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
166.1B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
148.9B USD |
25%
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on SCI Pharmtech Inc's most recent financial statements, the company has Operating Margin of 11.3%.
You don't have any saved screeners yet